These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 21393075)

  • 41. BRAF inhibitor activity in V600R metastatic melanoma.
    Klein O; Clements A; Menzies AM; O'Toole S; Kefford RF; Long GV
    Eur J Cancer; 2013 Mar; 49(5):1073-9. PubMed ID: 23237741
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: Potential predictive role of treatment efficacy.
    Consoli F; Manganoni AM; Grisanti S; Petrelli F; Venturini M; Rangoni G; Guarneri F; Incardona P; Vermi W; Calzavara Pinton PG; Berruti A
    PLoS One; 2019; 14(4):e0214884. PubMed ID: 30939167
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vemurafenib for the treatment of BRAF mutant metastatic melanoma.
    Martin-Liberal J; Larkin J
    Future Oncol; 2015; 11(4):579-89. PubMed ID: 25686114
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies.
    Dulgar O; Kutuk T; Eroglu Z
    Am J Clin Dermatol; 2021 Jan; 22(1):1-10. PubMed ID: 33368052
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy-Paradoxical ERK Activation and Beyond.
    Jung T; Haist M; Kuske M; Grabbe S; Bros M
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576054
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma.
    Rose AAN
    Drugs Today (Barc); 2019 Apr; 55(4):247-264. PubMed ID: 31050693
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of mutated, activated BRAF in metastatic melanoma.
    Flaherty KT; Puzanov I; Kim KB; Ribas A; McArthur GA; Sosman JA; O'Dwyer PJ; Lee RJ; Grippo JF; Nolop K; Chapman PB
    N Engl J Med; 2010 Aug; 363(9):809-19. PubMed ID: 20818844
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma.
    King JW; Nathan PD
    Future Oncol; 2014; 10(9):1559-70. PubMed ID: 25145427
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma.
    Amann VC; Hoffmann D; Mangana J; Dummer R; Goldinger SM
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1638-1640. PubMed ID: 28401596
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mitogen-Activated Protein Kinase Signaling Pathway in Cutaneous Melanoma: An Updated Review.
    Acosta AM; Kadkol SS
    Arch Pathol Lab Med; 2016 Nov; 140(11):1290-1296. PubMed ID: 27788045
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
    Welsh SJ; Rizos H; Scolyer RA; Long GV
    Eur J Cancer; 2016 Jul; 62():76-85. PubMed ID: 27232329
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
    Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
    J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition.
    Amaral T; Sinnberg T; Meier F; Krepler C; Levesque M; Niessner H; Garbe C
    Eur J Cancer; 2017 Mar; 73():85-92. PubMed ID: 28169047
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
    Daud A; Tsai K
    Oncologist; 2017 Jul; 22(7):823-833. PubMed ID: 28526719
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era.
    Vanella V; Festino L; Trojaniello C; Vitale MG; Sorrentino A; Paone M; Ascierto PA
    Curr Oncol Rep; 2019 Jul; 21(9):76. PubMed ID: 31359162
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.
    Montagut C; Sharma SV; Shioda T; McDermott U; Ulman M; Ulkus LE; Dias-Santagata D; Stubbs H; Lee DY; Singh A; Drew L; Haber DA; Settleman J
    Cancer Res; 2008 Jun; 68(12):4853-61. PubMed ID: 18559533
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma.
    Ben-Betzalel G; Baruch EN; Boursi B; Steinberg-Silman Y; Asher N; Shapira-Frommer R; Schachter J; Markel G
    Eur J Cancer; 2018 Sep; 101():229-235. PubMed ID: 30096703
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.
    Jalili A; Wagner C; Pashenkov M; Pathria G; Mertz KD; Widlund HR; Lupien M; Brunet JP; Golub TR; Stingl G; Fisher DE; Ramaswamy S; Wagner SN
    J Natl Cancer Inst; 2012 Nov; 104(21):1673-9. PubMed ID: 22997239
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition.
    Zimmer L; Hillen U; Livingstone E; Lacouture ME; Busam K; Carvajal RD; Egberts F; Hauschild A; Kashani-Sabet M; Goldinger SM; Dummer R; Long GV; McArthur G; Scherag A; Sucker A; Schadendorf D
    J Clin Oncol; 2012 Jul; 30(19):2375-83. PubMed ID: 22614973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.